Sanofi Maintains Growth Streak But Oncology Pipeline Renewal Efforts Stall

With Trial Discontinuation

The French major saw strong Q3 sales and raised its business guidance accordingly, but the discontinuation of an early-stage trial has added to a growing list of setbacks the firm has faced in reviving its oncology pipeline.    

Green arrow going up and pink arrow going down
News Of Strong Sales Were Dampened By Pipeline Doldrums • Source: Shutterstock

More from Earnings

More from Business